Biopharma Co. Misled Investors On Cancer Drug Progress: Suit

Law360, Los Angeles (October 31, 2013, 4:54 PM EDT) -- Vical Inc., which researches and develops biopharmaceutical products for the prevention and treatment of serious diseases, on Wednesday was hit with a putative class action in California federal court by a shareholder who says the company made false statements about the progress of cancer drug Allovectin-7.

Named plaintiff Joel Duncan, who seeks to represent investors who acquired Vical securities between Feb. 8, 2012, and Aug. 12, says Vical and certain of its officers and directors violated the Securities Exchange Act of 1934 by issuing materially false...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Duncan v. Vical Incorporated et al


Case Number

3:13-cv-02628

Court

California Southern

Nature of Suit

Securities/Commodities

Judge

Cynthia Bashant

Date Filed

October 30, 2013

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.